Linked Data API

Show Search Form

Search Results

170101
registered interest false more like this
date less than 2014-12-12more like thismore than 2014-12-12
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Breast Cancer: Tamoxifen more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what discussions his Department has had with the National Institute for Health and Care Excellence about a technology appraisal for tamoxifen in the chemoprevention indication. more like this
tabling member constituency Belfast East more like this
tabling member printed
Naomi Long more like this
uin 218545 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Our assessment is that, as NICE has already provided guidance on the use of tamoxifen and raloxifene, there would be little value in NICE separately appraising these drugs for the prevention of breast cancer and we have had no discussions with NICE on this issue.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218463 more like this
question first answered
less than 2014-12-17T17:20:27.857Zmore like thismore than 2014-12-17T17:20:27.857Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
3920
label Biography information for Naomi Long more like this
170102
registered interest false more like this
date less than 2014-12-12more like thismore than 2014-12-12
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Drugs: Licensing more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how many breast cancer clinicians he spoke to directly when developing his policy on the Off-patent Drugs Bill. more like this
tabling member constituency Belfast East more like this
tabling member printed
Naomi Long more like this
uin 218546 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>In developing our response to the Bill, we have taken advice from a number of cancer clinicians including breast cancer specialists and from officials at the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, and taken account of views expressed by other stakeholder organisations.</p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218462 more like this
question first answered
less than 2014-12-17T17:11:40.23Zmore like thismore than 2014-12-17T17:11:40.23Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
3920
label Biography information for Naomi Long more like this
170105
registered interest false more like this
date less than 2014-12-12more like thismore than 2014-12-12
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if he will make an assessment of the potential merits of allowing two Patient Access Schemes for one treatment; and if he will make a statement. more like this
tabling member constituency Southend West more like this
tabling member printed
Mr David Amess more like this
uin 218554 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218458 more like this
question first answered
less than 2014-12-17T17:16:52.86Zmore like thismore than 2014-12-17T17:16:52.86Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
44
label Biography information for Sir David Amess more like this
169841
registered interest false more like this
date less than 2014-12-11more like thismore than 2014-12-11
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Bladder Cancer: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the Anti-PD-L1 drug in treating bladder cancer. more like this
tabling member constituency Montgomeryshire more like this
tabling member printed
Glyn Davies more like this
uin 218285 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>Two Anti-PD monoclonal antibody products are being evaluated in clinical trials for various cancers, including bladder cancer.</p><p> </p><p> </p><p> </p><p>MPDL3280A, an anti-PD-L1 antibody made by Roche/Genentech, is undergoing a phase I trial (<a href="http://clinicaltrials.gov/ct2/show/NCT01375842" target="_blank">NCT01375842</a>) in patients with locally advanced or metastatic solid tumours. The estimated study completion date is November 2016. The product is also being tested in a phase II trial in in patients with locally advanced or metastatic urothelial bladder cancer (<a href="http://clinicaltrials.gov/ct2/show/NCT02108652" target="_blank">NCT02108652</a>). The estimated completion date for this Phase II trial is January 2016.</p><p> </p><p> </p><p> </p><p>The second anti-PD antibody is Nivolumab produced by Bristol-Myers Squibb. Nivolumab on its own, or in combination with another monoclonal antibody ipilimumab (Yervoy®), is in a phase I/II trial in several cancers, including bladder cancer (<a href="http://clinicaltrials.gov/show/NCT01928394" target="_blank">NCT01928394</a>). This trial is expected to be completed by March 2017.</p><p> </p><p> </p><p> </p><p>No assessment of the data from any of these trials has been made to date.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-12-17T17:36:02.357Zmore like thismore than 2014-12-17T17:36:02.357Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4041
label Biography information for Glyn Davies more like this
169864
registered interest false more like this
date less than 2014-12-11more like thismore than 2014-12-11
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Breast Cancer: Raloxifene more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he plans to take to ensure the routine availability of raloxifene to reduce the risk of breast cancer developing in high-risk women. more like this
tabling member constituency Coatbridge, Chryston and Bellshill more like this
tabling member printed
Mr Tom Clarke more like this
uin 218384 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p> </p><p /> <p>I refer the hon. Member to the Answer I gave the hon. Member for Bolton South East (<a href="http://www.parliament.uk/biographies/commons/yasmin-qureshi/3924" target="_blank">Yasmin Qureshi</a>) on 19 November 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-10/213936/" target="_blank">213936</a>.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-12-17T17:27:43.857Zmore like thismore than 2014-12-17T17:27:43.857Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
583
label Biography information for Mr Tom Clarke more like this
169978
registered interest false more like this
date less than 2014-12-11more like thismore than 2014-12-11
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, whether his Department has any plans to allow two Patient Access Schemes for one treatment; and if he will make a statement. more like this
tabling member constituency Southend West more like this
tabling member printed
Mr David Amess more like this
uin 218458 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218554 more like this
question first answered
less than 2014-12-17T17:16:52.76Zmore like thismore than 2014-12-17T17:16:52.76Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
44
label Biography information for Sir David Amess more like this
169982
registered interest false more like this
date less than 2014-12-11more like thismore than 2014-12-11
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Drugs: Licensing more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how many breast cancer clinicians his Department met directly when developing its position on the Off-patent Drugs Bill. more like this
tabling member constituency Bristol East more like this
tabling member printed
Kerry McCarthy more like this
uin 218462 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>In developing our response to the Bill, we have taken advice from a number of cancer clinicians including breast cancer specialists and from officials at the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, and taken account of views expressed by other stakeholder organisations.</p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218546 more like this
question first answered
less than 2014-12-17T17:11:40.34Zmore like thismore than 2014-12-17T17:11:40.34Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1491
label Biography information for Kerry McCarthy more like this
169997
registered interest false more like this
date less than 2014-12-11more like thismore than 2014-12-11
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Breast Cancer: Raloxifene more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what recent discussions his Department has had with the National Institute for Health and Care Excellence about that body conducting a technology appraisal for raloxifene in the chemoprevention indication. more like this
tabling member constituency Bristol East more like this
tabling member printed
Kerry McCarthy more like this
uin 218463 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Our assessment is that, as NICE has already provided guidance on the use of tamoxifen and raloxifene, there would be little value in NICE separately appraising these drugs for the prevention of breast cancer and we have had no discussions with NICE on this issue.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
grouped question UIN 218545 more like this
question first answered
less than 2014-12-17T17:20:27.73Zmore like thismore than 2014-12-17T17:20:27.73Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1491
label Biography information for Kerry McCarthy more like this